Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Fluvoxamine(click to collapse)
1/4 selected
Fluvoxamine
Luvox
Selective Serotonin Reuptake Inhibitor
FDA-approved indications
- Obsessive-compulsive disorder (adults; pediatric 8–17 years)
Off-label uses
- Social anxiety disorder
- PTSD
- Panic disorder
Half-life15.6 hours
Decision GuideWhen to pick each / when to consider an alternative
Fluvoxamine
Consider when
- OCD is the primary indication — only SSRI FDA-approved exclusively for OCD; strong evidence including pediatric (age 8–17)
- SSRI-induced sexual dysfunction is intolerable — lowest SD rates of any SSRI (FAERS ROR 1.08 erectile dysfunction, non-significant)
- Cardiac patient where QTc is the dominant concern — low QTc risk vs citalopram and escitalopram
- Patient on tamoxifen — weak CYP2D6 inhibitor (unlike fluoxetine/paroxetine); preserves endoxifen activation
- +1 more
Consider an alternative when
- Polypharmacy with theophylline, clozapine, olanzapine, or tizanidine — broadest CYP inhibition footprint of any SSRI (1A2, 2C19, 2C9, 3A4)
- Nausea sensitivity — class-top nausea 40% vs 14% placebo; leading cause of discontinuation
- MDD is the primary indication — not FDA-approved for MDD; lowest efficacy and acceptability among SSRIs in Cipriani 2018
- Daytime sedation poorly tolerated — somnolence 22% vs 8% placebo plus asthenia 14% vs 6%; highest sedation among SSRIs
- +1 more
Efficacy & Acceptability (2 axes)— NMA efficacy & discontinuation data (not side effects)
| Axis | Fluvoxamine |
|---|---|
| 📊 Efficacy (response rates) | |
MDDEfficacy | |
| 🛡️ Acceptability (all-cause discontinuation) | |
MDDAcceptability | |
| Axis | Fluvoxamine SSRI |
|---|---|
| Boxed Warnings | |
Suicidality (boxed warning) | |
Mania / hypomania induction | |
| CNS | |
Sedation / somnolence | |
Activation / insomnia | |
Seizure risk | |
| Metabolic | |
Weight gain | |
| Autonomic | |
Anticholinergic burden | |
Sweating | |
Angle-closure glaucoma | |
| Cardiac | |
QTc prolongation | |
| GI | |
Nausea / GI (general) | |
| Electrolytes | |
Hyponatremia / SIADH | |
| Sexual | |
Sexual dysfunction | |
| Discontinuation | |
Withdrawal / discontinuation | |
| Interactions | |
Serotonin syndrome risk | |
CYP interactions / DDI profile | |
| Safety | |
Bleeding risk | |
| Pregnancy | |
Lactation / breastfeeding safety | |
| Drug-specific / distinctive axes | |
Bradycardia — DISTINCTIVE NMA SIGNAL only in Fluvoxamine | |